ARTICLE
25 April 2017

EMTALA Liability Expands

DM
Duane Morris LLP

Contributor

Duane Morris LLP, a law firm with more than 800 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today's legal and business challenges.
A new OIG CMP rule effective January 6, 2017 clarifies the liability guidelines for EMTALA violations.
United States Food, Drugs, Healthcare, Life Sciences

A new OIG CMP rule effective January 6, 2017 clarifies the liability guidelines for EMTALA violations. The rule affirmed that willful conduct by a provider is not required for the OIG to impose penalties for EMTALA violations and revised the definition of "responsible physician" to clarify that on-call physicians at hospitals with specialized capabilities are considered responsible physicians subject to EMTALA.

The new rule removes "intent to leave" as a mitigating factor, adds "corrective action" as a mitigating factor and adds "risk of patient harm" as an aggravating factor. Because alleged EMTALA violations increasingly include allegations against the hospital and the responsible physician, a potential conflict of interest exists between the hospital and the responsible physician, due to the temptation to divert blame by pointing fingers. The hospital and the responsible physician should have separate legal counsel. For physicians, EMTALA violation findings can become medical license disciplinary actions.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More